Drug Pipeline

IMA203 Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
3
Active Studies
3
Recruiting
1
Phase 3
1
Top Sponsors
1
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-05-30 NCT06743126
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated…		 Trial sites expanded: 59 -> 66 locations
Active Studies by Phase
Phase 3
1
Phase 1/2
1
Phase 1
1
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT06743126 SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated… Melanoma, Cutaneous Malignant Recruiting
Phase 1/2
NCT03686124 ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent… Refractory Cancer Recruiting
Phase 1
NCT06946225 ACTengine® IMA203 Combined With mRNA-4203 Cutaneous Melanoma Recruiting
Sponsors Running IMA203 Trials
Immatics US, Inc. (3)
Disease Areas
Melanoma (2) Sarcoma (1)
Get alerts when IMA203 trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free